Onconetix, Inc. (ONCO)
0.4788
-0.07
(-12.63%)
USD |
NASDAQ |
Oct 16, 16:00
0.5301
+0.05
(+10.71%)
After-Hours: 20:00
Onconetix EPS Diluted (Quarterly) : -1.278 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.278 |
| March 31, 2026 | -67.06 |
| December 31, 2025 | 181.72 |
| September 30, 2025 | -312.48 |
| June 30, 2025 | -237.91 |
| March 31, 2025 | -2271.80 |
| December 31, 2024 | -10718.46 |
| September 30, 2024 | -2.930 |
| June 30, 2024 | -25.78 |
| March 31, 2024 | -20.08 |
| December 31, 2023 | -40.05 |
| September 30, 2023 | -12.21 |
| Date | Value |
|---|---|
| June 30, 2023 | -17.26 |
| March 31, 2023 | -7.157 |
| December 31, 2022 | -8.432 |
| September 30, 2022 | -10.79 |
| June 30, 2022 | -14.22 |
| March 31, 2022 | -13.67 |
| December 31, 2021 | -4.951 |
| September 30, 2021 | -4.642 |
| March 31, 2021 | -5.793 |
| December 31, 2020 | -1.974 |
| September 30, 2020 | -1.72 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Vistagen Therapeutics, Inc. | -0.3032 |
| BridgeBio Pharma, Inc. | -0.7775 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -2.867M |
| Revenue (Quarterly) | 0.0171M |
| Total Expenses (Quarterly) | 2.884M |
| Enterprise Value | -3.937M |
| Gross Profit Margin (Quarterly) | 25.15% |
| Profit Margin (Quarterly) | -16.77K% |
| Earnings Yield | -41.58K% |
| Normalized Earnings Yield | -53222.20 |